Two breast cancer drugs compared in the brains of mice
Original title: Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in mice, not in people.
The short version
In mice, one drug shrank brain tumors far more than the other did.
What was studied. Researchers put human triple negative breast cancer cells into the brains of mice. They then compared two drugs that aim at a target called TROP2, datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan (SG).
What they found. One dose of Dato-DXd shrank the tumors by 99.5% on average. SG shrank them by 1.8%. Mice that got no treatment lived 18 days. Mice given SG lived 48 days, and mice given Dato-DXd lived 83 days.
What this means, and what it doesn't
What it could mean: Dato-DXd may reach these brain tumors better than SG does. That is a hopeful sign, but it comes from mice, not people. The authors say the drug should now be studied in patients whose triple negative breast cancer has spread to the brain.
What it doesn't mean: This does not mean the drug works this way in people. No person was treated in this study. It was done in mice, which is very early research and far from everyday care. Many drugs that work in mice do not work in people. This is not a promise of a cure, and it is not something you can ask your doctor for today.
Source: PubMed, August 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.